Allegra Padula

Goodwin

Contact
View Bio
RSS

Latest Posts › Bristol-Myers Squibb

Share:

PTAB Discretionarily Denies Two Petitions, Refers a Third to the Board in Amgen v. Bristol-Myers Squibb

On July 24, 2025, Acting Director of the USPTO, Coke Morgan Stewart, denied institution of inter partes review in IPR2025-00601 and IPR2025-00602, but referred the petition in IPR2025-00603 to the Board in Amgen Inc. v....more

8/19/2025  /  Amgen , Biosimilars , BPCIA , Bristol-Myers Squibb , Inter Partes Review (IPR) Proceeding , Parallel Proceedings , Patent Trial and Appeal Board , Pharmaceutical Industry , Pharmaceutical Patents , USPTO
1 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide